Retatrutide 12.0 mg: Dosing Guide & What to Expect

When your prescriber recommends Retatrutide 12.0 mg, you're progressing through the standard dose escalation protocol. This guide covers the clinical evidence, typical side effect patterns, and titration guidance specific to this dose.

What Is Retatrutide 12.0 mg?

Retatrutide () is a GIP/GLP-1/Glucagon triple receptor agonist administered by weekly subcutaneous injection. The 12.0 mg dose is the maintenance dose in the standard titration protocol, designed to progressively increase receptor engagement and clinical efficacy.

Clinical trial data from TRIUMPH-3 demonstrates a mean weight loss of approximately 24.2% at the maximum dose (12.0 mg) in trial-eligible participants. Results at intermediate doses like 12.0 mg are typically lower.

Titration Schedule for Retatrutide

Retatrutide 12.0 mg is the maximum approved dose. Most patients remain at this maintenance dose for the duration of treatment. Discuss long-term continuation with your prescriber.

Side Effects at 12.0 mg

The most commonly reported side effects of Retatrutide include GI-related symptoms that tend to be most pronounced during dose escalation. At 12.0 mg (a higher titration step), some patients experience more pronounced GI symptoms than at lower doses.

• •Nausea
• •Diarrhea
• •Vomiting
• •Constipation
• •Fatigue
• •Injection Site Reaction
• •Decreased Appetite

Most side effects are transient and improve within 2–4 weeks at a stable dose. GI symptoms (nausea, diarrhea, constipation) are the most common reasons for dose reduction or discontinuation.

When to Call Your Doctor

• Persistent vomiting preventing adequate hydration
• Severe abdominal pain that does not resolve
• Signs of pancreatitis (severe upper abdominal pain radiating to back)
• Any signs of allergic reaction
• Heart rate increase of >20 bpm at rest that persists

When to Escalate from 12.0 mg

Standard protocol calls for 4 weeks at each dose level before escalation, provided the dose is well tolerated. If side effects are significant, your prescriber may recommend staying at 12.0 mg for an additional 4 weeks (an 8-week interval) before moving up.

Do not escalate doses without prescriber guidance. Self-directed dose escalation increases the risk of adverse events.

Contraindications & Safety

This medication is investigational and not approved for clinical use outside of clinical trials. Key contraindications include:

• Investigational drug — contraindications not yet fully established
• Likely similar to other GLP-1 based therapies

Pregnancy: Investigational — not established. Discuss with your prescriber if pregnancy is a possibility.